Veradermics, Incorporated

Veradermics, Incorporated Current Assets

The Current Assets of Veradermics, Incorporated (MANE) as of Oct 21, 2026 is 151.24 M USD. In the previous year, Current Assets was 54.16 M USD — a change of 179.24% (higher).

Current Assets

151.24 MUSD

YoY

179.24%

Last updated:

Current Assets of Veradermics, Incorporated is 2025 151.24 M USD. Current Assets of Veradermics, Incorporated was 2024 54.16 M USD. It decreases by 179.24% higher compared to the previous year.

The Veradermics, Incorporated Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2023
17.56 M USD
Jan 1, 2024
54.16 M USD
Jan 1, 2025
151.24 M USD
The Veradermics, Incorporated Current Assets history
YEARCurrent AssetsYoY
151.24 MUSD+179.24%
54.16 MUSD+208.39%
17.56 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veradermics, Incorporated Stock analysis

What does Veradermics, Incorporated do? Veradermics, Incorporated develops novel therapeutics for dermatologic and aesthetic conditions, focusing on treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy, and VDMN, a dissolvable microarray patch technology for immunotherapy of common warts. VDAA targets alopecia areata, while VDMC addresses molluscum contagiosum. These products are used for treating androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in adult and pediatric populations, as well as the broader medical and clinical research community in dermatology. The company's revenue streams are derived from partnerships with healthcare providers and clinical research organizations for product development and clinical trials. These collaborations enable Veradermics to advance its pipeline of treatments, including VDPHL01, VDMN, VDAA, and VDMC, toward regulatory approval and commercialization. The primary buyers of Veradermics' services are healthcare providers and clinical research organizations involved in dermatology, with a focus on adult and pediatric dermatologic care and research. Veradermics operates within the clinical-stage biopharmaceutical sector, targeting dermatologic and aesthetic conditions. Its products are designed for specific conditions such as androgenetic alopecia, common warts, molluscum contagiosum, and alopecia areata, serving both adult and pediatric patient segments. The company's development activities are supported by partnerships with healthcare providers and clinical research organizations, which provide the necessary expertise and infrastructure for clinical trials and product advancement. Veradermics, Incorporated is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veradermics, Incorporated stock

Current Assets of Veradermics, Incorporated is 151.24 M USD in 2025.

Current Assets of Veradermics, Incorporated changed from 54.16 M USD to 151.24 M USD, representing a 179.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Veradermics, Incorporated since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Veradermics, Incorporated historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Veradermics, Incorporated

All Key Metrics — Veradermics, Incorporated